The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Pazopanib prior to planned nephrectomy in metastatic clear cell renal cancer: A clinical and biomarker study.
Thomas Powles
Honoraria - Astellas Pharma; Bayer; GlaxoSmithKline; Novartis; Pfizer
Research Funding - Astellas Pharma; Bayer; GlaxoSmithKline; Novartis; Pfizer
Naveed Sarwar
No relevant relationships to disclose
Andrew Stockdale
No relevant relationships to disclose
Ekaterini Boleti
Other Remuneration - GlaxoSmithKline
Robert J. Jones
Honoraria - Astellas Pharma; Bayer; GlaxoSmithKline; Novartis; Pfizer
Research Funding - Astellas Pharma; GlaxoSmithKline; Novartis; Pfizer
Andrew Protheroe
Honoraria - GlaxoSmithKline; Pfizer
Simon Chowdhury
Honoraria - GlaxoSmithKline; Pfizer
John Peters
No relevant relationships to disclose
Grenville Oades
No relevant relationships to disclose
Tim S. O'Brien
No relevant relationships to disclose
Mark Sullivan
No relevant relationships to disclose
Grant Stewart
No relevant relationships to disclose
Michael Aitchison
No relevant relationships to disclose
Shah-Jalal Sarker
No relevant relationships to disclose
Dan Berney
No relevant relationships to disclose
Charlotte Rofe
No relevant relationships to disclose
Kevin Sharpe
No relevant relationships to disclose
Simon J. Crabb
No relevant relationships to disclose